Last updated: February 14, 2026
Overview of NDC 81520-0255
NDC 81520-0255 is identified as Treprostinil injection. It is used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the lungs' arteries. This drug is marketed by United Therapeutics and has received regulatory approval from the FDA.
Market Size and Demand Dynamics
Therapeutic Area: PAH treatment market, with expanding indications due to advances in diagnosis and increased disease awareness.
Prevalence: PAH affects approximately 15-50 individuals per million globally, with the U.S. prevalence estimated at around 30,000 cases. Treprostinil typically accounts for approximately 60-70% of PAH-specific therapies, amidst an evolving treatment landscape.
Market Penetration: Treprostinil is administered via intravenous, subcutaneous, inhalational, and oral routes. The injection form, NDC 81520-0255, primarily serves severe cases requiring continuous infusion.
Competitive Landscape:
- Remodulin (Treprostinil): The primary competitor, with similar indications.
- Epoprostenol (Flolan): More established but with a shorter half-life.
- Riociguat (Adempas): Oral alternative, expanding treatment options.
Market Trends:
- Increasing adoption of prostacyclin pathway agents.
- Growing patient population due to better diagnostics.
- Shift towards oral formulations, potentially impacting injectable therapy demand.
Historical Pricing and Cost Trends
Price Data (as of 2022):
- The wholesale acquisition cost (WAC) for Treprostinil injection (NDC 81520-0255) ranges between $10,000 to $12,000 per 10 mL vial.
- The average monthly cost per patient ranges from $30,000 to $50,000, dependent on dosage and infusion duration.
Pricing Drivers:
- Manufacturing complexity of infusion devices.
- Moderate competition within the prostacyclin class.
- Regulatory exclusivity; Treprostinil patents expired in 2021, opening the market for biosimilars, which could pressure prices downward.
Price Projections (2023-2027)
| Year |
Projected Price Range (per 10 mL vial) |
Assumptions and Drivers |
| 2023 |
$10,500–$11,500 |
Stable demand; biosimilar entry limited initially |
| 2024 |
$10,000–$11,000 |
Biosimilar market entry begins; slight price erosion |
| 2025 |
$9,500–$10,500 |
Increased biosimilar competition; price stabilization |
| 2026 |
$9,000–$10,000 |
Greater biosimilar adoption; cost pressures mounting |
| 2027 |
$8,500–$9,500 |
Continued biosimilar market expansion, margins compress |
Factors Influencing Price Trajectory
- Biosimilar Competition: Entry expected no earlier than 2023-2024; prices could decrease by 10-20% depending on market uptake.
- Regulatory Dynamics: Potential patents or exclusivities could restrict biosimilar entry or elongate pricing stability.
- Market Growth: An expanding patient base and increasing diagnosis rates could sustain revenues despite price erosion.
- Supply Chain Factors: Raw material costs and manufacturing complexity impact pricing stability.
Regulatory and Commercial Outlook
Regulatory Status: FDA approval for Treprostinil injection remains active, with ongoing patent challenges and explicit pathways for biosimilar approval.
Commercial Strategy: Focused on hospital and specialty infusion centers, with a significant number of patients heavily dependent on the existing formulation, providing a base for sustained revenue.
Key Competitor Pricing Projection
| Competitor |
Approximate Price Range (2023) |
Market Share Impact |
| Remodulin |
Similar or slightly higher |
25-30% of PAH market |
| Epoprostenol |
Slightly lower, variable |
10-15% |
Summary
NDC 81520-0255, Treprostinil injection, is positioned in a niche high-cost, high-demand segment of the PAH treatment market. The current price of around $10,000–$12,000 per vial is poised for gradual decline over the next five years, primarily due to biosimilar competition and market expansion of alternative therapies.
Key Takeaways
- The drug has stable demand in severe PAH cases, with prices averaging $10,000–$12,000 per vial.
- Biosimilar entry from 2023-2024 could erode prices by 10-20% over the subsequent years.
- Market growth driven by increased PAH diagnosis supports revenue stability despite declining prices.
- Manufacturers will need to adapt to biosimilar competition and shifting treatment paradigms.
FAQs
1. When will biosimilar versions of Treprostinil injection enter the market?
Expected between 2023 and 2024, depending on regulatory approvals and patent challenges.
2. How does Treprostinil compare cost-wise to other PAH treatments?
It remains among the higher-cost options, especially in injectable form, with monthly costs around $30,000–$50,000.
3. What factors could influence price stability beyond biosimilar competition?
Supply chain costs, regulatory exclusivity, and the adoption of alternative therapies impact pricing stability.
4. What market segments are most likely to be affected by price declines?
Hospital infusion centers and specialty clinics relying on the injectable form will experience the most impact.
5. How does patient prevalence influence future market projections?
A growing diagnosed population and improved disease awareness support sustained demand, mitigating some negative pricing effects.
References
- U.S. Food and Drug Administration. Treprostinil Injection Labeling.
- IQVIA. National Prescription Data 2022.
- Evaluate Pharma. Pediatric and Adult PAH Market Reports 2022.
- Center for Drug Evaluation and Research. Patent and Biosimilar Guidelines.
- United Therapeutics Corporation. Financial and Market Reports.
